A clinicoetiological study of Stevens-Johnson syndrome and toxic epidermal necrolysis


  • Syed AhmadSyed Ali Gardezi
  • Atif Hasnain Kazmi
  • Shahbaz Aman
  • Muhammad Nadeem
  • Muhammad Salim Khan
  • Masood Sohail


Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis


Objectives To present the pattern of morbidity associated complications, and causative factors in individual cases of Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). Patients and methods This case series descriptive study, using a convenience sampling technique, was carried out in the In-patients department of Dermatology Unit I, Mayo Hospital, King Edward Medical University, Lahore from January 2007 to September 2008. Thirty clinically diagnosed patients, suffering from SJS/TEN, fulfilling the inclusion criteria were included in the study. Patients’ demographic data, symptoms, signs and any relevant investigations were recorded and scored. Using an appropriately designed pro forma, symptoms/ and signs were categorized into thirteen variables. The severity of each variable was scored from1-3 (total score range 13 to 39). An association of these variables with patient outcome, in terms of either discharge from hospital or death, was calculated. Results Pain and gastrointestinal involvement were seen in all 30 (100%) patients. Mortality was found to be 13.3% and was significantly associated with infection, total morbidity score, area of epidermal involvement and respiratory system involvement. Similarly development of wound infection, area of epidermal involvement, fever and total score significantly affected the duration of hospital stay. While the causative drug/s remained unknown in 26.7% cases the most common identifiable drug was trimethoprim-sulphamethoxazole, causing disease in 13.3%. Conclusions Mortality in cases of SJS/TEN showed significant association with wound infection, area of skin involvement, total morbidity score and respiratory system involvement. 


Klein PA, Dirk M, Elston DE. Dermatologic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis [online] 2011 Oct 20 last update. Available from: URL: http://emedicine.medscape.com/article/1124127-overview#aw2aab6b3Martin T, Hui LI. Severe cutaneous adverse drug reactions: a review on epidemiology, etiology, clinical manifestation and pathogenesis. Chin Med J. 2008;121:756-61.

Halevy S. Stevens-Johnson syndrome and toxic epidermal necrolysis--updates and innovations. Harefuah. 2010;149:186-90, 193.

Yapp FBB, Wahiduzzaman M, Pubalan M. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in Sarawak: A four years review. Egyp Dermatol Online J. 2008;4:1.

Lissia M, Mulas P, Bulla A et al. Toxic epidermal necrolysis (Lyell's disease). Burns. 2010;36;152-63.

Koh MJ, Tay YK. An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Curr Opin Pediatr. 2009;21:505-10.

Ahmed YI, Azeem S, Khan O et al. Stevens-Johnson syndrome in Pakistan: a ten year survey. J Pak Med Assoc. 2004;54:312-5.

Foster SC, Letko E. Stevens-Johnson syndrome [online] 2007 Dec 18 last update. [Cited 2007 Dec 20]. Available from: URL:http://www.emedicine.com/oph/topic268.html

Sanmarkan AD, Sori T, Thappa DM, Jaisankar TJ. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis over a period of 10 years. Indian J Dermatol. 2011;56:25-9.

Wolkenstein P, Revuz J. Toxic epidermal necrolysis. Dermatol Clin 2000;18:485-95.

Levi N, Bastuji-Garin S, Mockenhaupt M et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123:e297-304.

Barvaliya M, Sanmukhani J, Patel T et al. Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study. Postgrad Med. 2011;57:115-9.

Martin T, Li H. Severe cutaneous adverse drug reactions: a review on epidemiology, etiology, clinical manifestation and pathogenesis. Chin Med J (Engl). 2008;121:756-61.

Parrillo SJ, Parrillo CV. Stevens Johnson Syndrome [online] 2007 Feb 22 last update. [cited 2007 Dec 21]. Available from: URL:http://www.emedicine.com/EMERG/topic555.html.

de Prost N, Ingen-Housz-Oro S, Duong T et al. Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures. Medicine (Baltimore). 2010;89:28-36.

French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int. 2006;55:9-16.

Gurcan HM, Ahmed AR. Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders. Ann Pharmacother. 2007;41:812-23.

Burk M, Sood A. Acute pulmonary manifestations of toxic epidermal necrolysis. J Burns Surg Wound Care. 2003;2:6. [cited 2007 Dec 24]. Available from: URL:http://www.journalofburns.com.




How to Cite

Gardezi SAA, Kazmi AH, Aman S, Nadeem M, Khan MS, Sohail M. A clinicoetiological study of Stevens-Johnson syndrome and toxic epidermal necrolysis. J Pak Assoc Dermatol [Internet]. 2016Dec.9 [cited 2024Jun.24];23(1):5-13. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/254



Original Articles

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>